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Abstract: Campylobacter jejuni (C. jejuni) bacteremia is difficult to diagnose in individuals with
hematological disorders undergoing chemotherapy. The cause can be attributed to the rarity
of this infection, to the variable clinical presentation, and to the partial overlapping symptoms
underlying the disease. Here, we report a case of a fatal sepsis caused by C. jejuni in a 76-year-old
Caucasian man with non-Hodgkin’s lymphoma. After chemotherapeutic treatment, the patient
experienced fever associated with severe neutropenia and thrombocytopenia without hemodynamic
instability, abdominal pain, and diarrhea. The slow growth of C. jejuni in the blood culture
systems and the difficulty in identifying it with conventional biochemical phenotyping methods
contributed to the delay of administering a targeted antimicrobial treatment, leading to a fatal
outcome. Early recognition and timely intervention are critical for the successful management
of C. jejuni infection. Symptoms may be difficult to recognize in immunocompromised patients
undergoing chemotherapy. Thus, it is important to increase physician awareness regarding the clinical
manifestations of C. jejuni to improve therapeutic efficacy. Moreover, the use of more aggressive
empirical antimicrobial treatments with aminoglycosides and/or carbapenems should be considered
in immunosuppressed patients, in comparison to those currently indicated in the guidelines for
cancer-related infections supporting the use of cephalosporins as monotherapy.
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1. Introduction
Campylobacter jejuni represents one of the most common worldwide causes of bacterial
gastroenteritis with over 190,000 cases occurring annually in the 27 member states of the European
Union (www.efsa.europa.eu/efsajournal). Clinical manifestations include abdominal pain, fever, and
diarrhea [1].
Unlike other enteric infections, C. jejuni is only rarely associated with extraintestinal localization
and systemic invasive illness [1,2]. Bacteremia caused by C. jejuni has been detected in less than 1% of
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patients with gastroenteritis and it has been mainly reported in elderly and in immunocompromised
patients [1,2].
In this study, we describe a case of C. jejuni sepsis in a patient with non-Hodgkin’s lymphoma
that resulted in a fatal outcome. The low incidence of C. jejuni bacteremia and the paucity of associated
symptoms make this infection difficult to detect in patients with hematological disorders where
selecting the appropriate antibiotic treatment is crucial, and at present, early and distinctive clinical
features have not yet been fully elucidated.
2. Case Presentation
A 76-year-old man was hospitalized in our Department of Hematology of the “Regina Elena”
National Cancer Institute in Rome on 13 March, 2014. He suffered from a Diffuse Large B-Cell
Lymphoma that had evolved from a previously diagnosed indolent non-Hodgkin Lymphoma (NHL)
which was refractory to three chemo-immunotherapeutic lines of treatment and was characterized by
cerebral and meningeal involvement at the time of last progression.
Upon admission, the patient had evening fever and severe dysarthria (Figure 1). On March 14,
he received an urgent salvage treatment based on a chemo-immunotherapeutic regimen containing
Rituximab 375 mg/m2 on day 1, Methotrexate 1 g/m2 on day 2, and Cytarabine 1 g total dose twice
daily, for days 3 and 4. Given the presence of evening fevers and a moderate increase in procalcitonin
levels (mini VIDAS system, bioMérieux, Florence, Italy) to 2.62 ng/mL (normal, <0.5 ng/mL),
an empirical antibiotic therapy was administered including Ceftriaxone (2 g daily) at the beginning
of the salvage chemo-immunotherapy, even in the absence of any microbiological evidence from the
blood cultures and surveillance swabs. After 48 h, a complete regression of fever and a decrease in
procalcitonin levels to 1.69 ng/mL were observed. Serial blood cultures, taken on March 18, were
incubated in an automated, noninvasive culture system (BacT/ALERT, bioMérieux, Florence, Italy).
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On March 19, the hemocytometric assessment showed severe neutropenia and thrombocytopenia
(hemoglobin 75 g/liter, platelet count 6 ˆ 109/liter, white blood cell count 0.06 ˆ 109/liter). On March
20, the stool culture exam gave negative results. Nevertheless, on March 21, the patient had a relapse
(fever > 39 ˝C) in the absence of symptoms indicating hemodynamic instability as well as abdominal
pain or diarrhea. Based on the assumption that the patient was undergoing a sepsis, the patient
was empirically treated with intravenous Piperacillin-Tazobactam (4.5 g three times a day), without
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clinical improvement. The abdominal echography revealed a severe circumferential thickening of
the cecum wall with submucosal edema, whereas procalcitonin levels increased to 3.64 ng/mL.
Meanwhile, on March 22, the blood cultures were positive revealing curved gram-negative rods at the
microscopic analysis. The organism was subcultured onto chocolate agar (bioMérieux, Florence,
Italy) and then incubated at 36 ˝C in a microaerophilic environment with 5% CO2. Thus, on
March 23, based on the abdominal echography (suggestive for ileotiphlitis), and the patient’s general
clinical conditions and increased procalcitonin levels, even in the absence of microbiological data
(blood cultures were negative, so far), a different antibiotic therapeutic regimen was implemented.
The patient was administered Tygeciclin 50 mg intravenously twice a day after a loading dose of
100 mg, Metronidazole 500 mg four times a day, and Caspofungin 50 mg daily after a loading dose
of 70 mg. Despite implementing this type of antibiotic treatment, a rapid clinical deterioration in the
patient was observed. Additionally, on March 23, cellulitis in the patient’s left leg was observed during
a dermatological consultation. However, a skin biopsy was not advised due to the general health
condition of the patient.
After 48 h of incubation, on March 24, irregular shaped grey and flat colonies appeared on the
chocolate agar plates. The isolate was initially identified as C. jejuni by distinct colony morphology
and by conventional biochemical tests resulting in oxidase- and hippurate-positive results.
Despite the microbiology laboratory promptly notifying the possible or likely infection of
C. jejuni and the immediate implementation of empirical intravenous treatment with Gentamicin
6 mg/kg/Die, a further worsening of the patient’s clinical condition was observed on March 24.
Surprisingly, microbiological testing by VITEK 2 system (bioMérieux, Florence, Italy) initially identified
the microorganism as Francisella Tularensis (96% of identification confidence) whereas repeated
testing yielded Moraxella spp. (95% of identification confidence), thereby creating uncertainty in
the identification of the microorganism present. Thus, the poor health condition of the patient
and severe cytopenia (hemoglobin 69 g/liter, platelet count 3 ˆ 109/liter, and white blood cell
count 0.5 ˆ 109/liter) contributed to a rapid fatal outcome on March 26. Further identification of
the microorganism was performed by sequence analysis (ABI PRISM 3130xl Genetic Analyzer) of the
16S rRNA gene [3]. The sequence showed 99.9% similarity and 100% coverage for the strains of C. jejuni
subsp. jejuni ATCC 700819. The sequences were deposited in the European Nucleotide Archive (ENA)
with accession number LN864495.
Antimicrobial susceptibility testing (AST) was performed by Etest®, according to the Clinical and
Laboratory Standards Institute (CLSI) breakpoints for non-Enterobacteriaceae as follows: ciprofloxacin,
§1 µg/mL (Sensitive); doxycycline, §4 µg/mL (Sensitive); gentamicin, §4 µg/mL (Sensitive);
meropenem, §4 µg/mL (Sensitive) (Table 1).
Table 1. Antibiotic susceptibility testing of the isolated bacteria.
Antibiotic Tested MIC Test Result
Ciprofloxacin §1 µg/mL Sensitive
Doxycycline §4 mcg/mL Sensitive
Gentamicin §4 mcg/mL Sensitive
Meropenem §4 mcg/mL Sensitive
MIC: Minimal Inhibitory Concentration performed by Etest® (bioMérieux, Florence, Italy), according to the
Clinical and Laboratory Standards Institute (CLSI) breakpoints for non-Enterobacteriaceae.
The Central Ethics Committee I.R.C.C.S. Lazio, section of the Istituti Fisioterapici Ospitalieri in
Rome, in compliance with the Helsinki Declaration, approved this case report (Prot. CE/1016/15—4
December 2015).
Data and relevant scientific articles were identified via specific PubMed database searches from
January 1980 and December 2015. The terms included in the search comprised: “Campylobacter jejuni”
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and “bacteremia” or “Campylobacter” and “bacteremia” or “non-Hodgkin’s lymphoma”. Research
was restricted to English language articles.
3. Discussion
Infections caused by C. jejuni are only rarely complicated by extraintestinal localization or
bacteremia [1]. In immunocompetent patients, C. jejuni bacteremia can be transient and resolved
without antimicrobial therapy [1]. Conversely, individuals with immune deficiency or another
serious underlying condition (cardiovascular disorders, hematological malignancies, liver disease,
hypogammaglobulinemia, and human immunodeficiency virus infection) are exposed to an increased
risk of bacteremia due to C. jejuni [2,4]. In these individuals, an effective antimicrobial treatment has
been significantly associated with an improved outcome [2]. In a large number of cases, a timely
identification of the pathogen and appropriate empirical antimicrobial therapy are hampered by the
atypical presentation of the symptoms caused by C. jejuni [1,2]. The clinical signs of Campylobacter
bacteraemia are generally accompanied by an acute-onset febrile illness of a transient nature
with self-limiting enteritis. Nevertheless, in a large percentage of cases the clinical presentation
of Campylobacter bacteraemia may show a febrile illness without gastrointestinal symptoms [4].
Other typical manifestations observed in severe sepsis caused by Campylobacter may include, skin
lesions, cytopenia, and diarrhea, however, these symptoms also occur frequently in patients with
aggressive lymphomas undergoing chemotherapy [2]. Moreover, the absence of consensus on the
optimal antibiotic regimen and the lack of studies comparing different empirical treatments for C. jejuni
bacteraemia make it difficult for the clinician to select an appropriate antimicrobial therapy. Different
strategies were adopted, including fluoroquinolones (ciprofloxacin), macrolides (erythromycin), and
aminoglycosides (gentamicin) [5].
Fluoroquinolones (e.g., ciprofloxacin) were largely used for the treatment of Campylobacter
infection and, in general, are considered the drugs of choice for the empirical treatment of diarrheal
illnesses [6–8]. Campylobacter and other organisms, such as Salmonella or Shigella species, were
generally susceptible to fluoroquinolones, thus empirical treatment with these drugs is used
without waiting for the stool culture results. However, since the early 1990s a growing number
of fluoroquinolone-resistant Campylobacter strains have been registered in Asia as well as in several
European countries. This increase of resistant strains is not only the result of the excessive use of these
antimicrobials in clinical practice, but it is also the consequence of the use of fluoroquinolones in food
producing animals and in veterinary species [9–11]. Thus, the possibility of fluoroquinolone-resistant
strains must be considered in all cases of Campylobacter bacteraemia.
In the presence of confirmed Campylobacter infections, macrolides (erythromycin, or alternatively
clarithromycin or azithromycin) represent the frontline agents [12], with tetracycline, doxycycline,
and chloramphenicol considered alternative drugs [8]. However, recent evidence suggests that
Campylobacter is also becoming increasingly resistant to macrolides, which represents a rising concern
for public health [13]. The use of macrolides at subtherapeutic levels in chickens is considered a major
factor influencing the emergence of resistant strains [13–15]. Thus, for serious systemic infections
it has been demonstrated that aminoglycoside, gentamicin, or carbapenems are the most efficient
antimicrobials [2,4,8,16,17].
In our case, the absence of clear clinical signs of a possible infection with enteric pathogens
suggested that the patient be treated with ceftriaxone in accordance with the guidelines for
cancer-related infections in immunosuppressed patients that support the use of cephalosporins in
monotherapy [18]. Third-generation cephalosporins are largely used for the empirical treatment of
community-acquired infectious diarrhea. However, these antimicrobial agents have not been proven
effective for treating bacteremia due to Campylobacter species other than Campylobacter fetus [2,19].
Moreover, the use of third-generation cephalosporins and fluoroquinolones in the treatment of
Campylobacter bacteraemia has shown poor prognosis and a high frequency of resistant strains has
resulted in a general discouragement towards using this class of antibiotics [4,20], particularly
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in hospitals and communities with a high prevalence of extended-spectrum beta-lactamases
(ESBLs)-producing bacteria.
After the first antimicrobial treatment, the patient presented neutropenia and fever, and therapy
was then subsequently changed. In the absence of relevant microbiological data, the guidelines for the
empirical therapy of febrile neutropenic cancer patients receiving chemotherapy recommend the use
of pipercillin-tazobactam as first line monotherapy for the treatment of bloodstream infections [21].
However, Campylobacter isolates are not regularly susceptible to penicillins [22–24] and the b-lactamase
enzyme found in C. jejuni is preferentially inhibited by clavulanic acid, but not by tazobactam or
sulbactam [22,24]. In our case, only after having diagnosed sepsis caused by C. jejuni, the patient was
empirically treated with gentamicin and the subsequent susceptibility drug profile indicated that this
strain was in fact susceptible to this antimicrobial (Table 1). Nevertheless, the patient died because of
complications due to a septic status and multiorgan failure. It is important to note that the treatment
with gentamicin in this patient had started long after the appearance of initial enteric symptoms
(diarrhea) and the first signs of sepsis. The delayed start of the targeted antimicrobial treatment was
due to the difficulty in identifying C. jejuni bacteraemia, which, in turn, was the consequence of the very
slow growth of this bacterium in standard automatic blood culture systems [25]. In fact, blood cultures
are only rarely performed in patients presenting an apparently simple diarrhea symptom. This, as
well as the slow growth of the characteristics of C. jejuni and the self-limited nature of this infection
may represent a contributing cause to underestimating the real incidence of C. jejuni bacteraemia [26].
Additionally, the inability of the automated biochemical phenotyping system to promptly and correctly
identify C. jejuni further deferred the recognition of the pathogen. The slow growth of C. jejuni in
the BacT/ALERT and the repeated unsuccessful attempts in identifying the bacteria reported for the
VITEK 2 system made the recognition of this pathogen particularly elusive. Indeed, previous studies
have demonstrated that despite the Neisseria-Haemophilus (NH) identification card for VITEK 2
correctly identifying most C. jejuni ssp. Jejuni, misclassifications occur at a rate of more than 10% [27].
In this case, the diagnosis, and consequently the start of an appropriate therapy, was further delayed
by the negative result of the stool cultures after the first episodes of diarrhea. Diarrheal illnesses in
patients with neoplasia and immunosuppressive therapy are rarely perceived as a necessity to perform
blood cultures, even when there is a fever present. On the other hand, it should be considered that
blood stream infections caused by C. jejunimight occur without evidence of diarrhea, suggesting that
this bacterium can access the intestinal mucosa without causing local inflammation [28].
A retrospective study suggested that a diagnostic clue for the presence of C. jejuni infection might
be represented by leukopenia or thrombocytopenia, particularly when associated with an acute febrile
diarrheal illness [29]. However, in neoplastic and immune suppressed patients, such as in our case, the
marked cytopenia might be interpreted as a result of the immunosuppressed status of the patient who
underwent a chemo-immunotherapeutic program.
In addition, three days before the fatal outcome, the patient also experienced the occurrence
of cellulitis of the left leg. It has been reported that, although less recognized, skin lesions may
represent a complication of Campylobacter bacteraemia that occurs particularly in patients with
immune-related problems [30]. Again, the presence of NHL and chemotherapy made it difficult
to recognize cellulitis as a sign of C. jejuni infection since lymphomas can be also characterized by
an initial skin presentation [31].
4. Conclusions
In summary, although C. jejuni bacteraemia is uncommon, it may develop either primarily or
secondarily from gastroenteritis, and thereby may represent a severe disease for immunocompromised
individuals [30]. Occasionally, both NHLs and C. jejuni sepsis may intertwine; in cases such as
this, it may create difficulties in being able to make a plain distinction between the root cause(s) of
a patient’s symptoms. Many hematological disorders, especially lymphoid neoplasms, have a high
risk for infection, thus when dealing with immunocompromised patients a septic disease should be
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suspected even in the presence of mild symptoms. In aggressive lymphoma, and in patients undergoing
chemotherapy, fatigue, fever, diarrhea, as well as skin lesions and cytopenia may occur frequently, but
these symptoms may occur also in severe sepsis caused by C. jejuni. Recognizing the early symptoms
of a C. jejuni bacteraemia in hematological patients is key to initiate an effective antimicrobial therapy.
From our experience, and from the data reported in the literature [2,4], blood cultures should always
be performed in febrile patients with gastroenteritis. Therapy with appropriate antimicrobial agents
is an important component in the management of immunocompromised patients with C. jejuni
bacteraemia. Guidelines for cancer-related infections in immunosuppressed patients support the use of
cephalosporins in monotherapy [18], whereas for the treatment of febrile neutropenic cancer patients
receiving chemotherapy the use of pipercillin-tazobactam is recommended [21]. From our study, and
from the data reported in the literature, it emerged that immunosuppressed patients with suspected
Campylobacter sepsis should receive a more aggressive antimicrobial treatment—possibly combining
aminoglycosides and/or carbapenems with cephalosporins in the first line antimicrobial empirical
treatment. Nevertheless, the risk caused by the rise in antibiotic resistance among bacteria, particularly
with Campylobacter spp. should also be considered where an increase in the administration of multiple
antibiotics is likely to lead to colonization and infection with antibiotic-resistant organisms [32].
In this case, the unequivocal identification of C. jejuni was not obtained in time, and only by
sequence analysis of the 16S rRNA gene. This further suggested that diagnostic systems, other than
those based on the biochemical identification (i.e., molecular techniques and Mass Spectrometry—MS)
should be preferred for a prompt and unequivocal laboratory identification of C. jejuni. Combined
molecular protocols (such as 16S rRNA PCR, DNA sequencing, and Multilocus Sequence Typing
(MLST) analysis) revealed the successful identification of C. jejuni strains from stool and from blood
cultures, even in patients where traditional culture protocols failed [33–36]. These results demonstrate
the potential of molecular methods in improving the diagnosis of bacterial infections caused by C. jejuni.
Numerous PCR-based techniques (real-time PCR and pyrosequencing) have also been developed
for the rapid detection and identification of bacteria in clinical blood specimens [37]. Commercially
available real-time PCR for the direct detection of bacteria in blood has been introduced [38], but the
use of these tools has not become routine in clinical microbiology laboratories. Indeed, molecular
techniques are rather costly, and require people with high levels of technical expertise, and therefore
these techniques are consequently not suitable for routine identification, particularly in institutes with
limited financial resources or in developing countries. Moreover, the high sensitivity of PCR-based
methods and DNA sequencing that have the potential to detect all bacterial DNA present in a clinical
sample may cause serious problems in clinical interpretation. Background levels of bacterial DNA
might be detected in the blood of patients in the absence of any signs of bacteremia [39].
Matrix Assisted Laser Desorption Ionization Time-Of-Flight (MALDI-TOF) MS is a reliable tool
for a rapid, precise, and cost-effective classification of a broad spectrum of bacteria and yeast [40].
MALDI-TOF MS analysis was in complete agreement with molecular tests identifying C. jejuni and
C. coli [41]. Moreover, changes in protein biomarkers, such as those caused by an amino acid
substitution, have been used to differentiate between C. jejuni ssp. jejuni and subsp. doylei, and
to assess phylogenetic relationships in different isolates [42]. Several studies have evaluated the
contribution of MALDI-TOF MS towards identifying microorganisms in positive blood culture [40,43].
Results showed that MALDI-TOF MS accurately identified blood-borne organisms in more than 80%
of cases. Nevertheless, the ability of MALDI-TOF MS to correctly identify microorganisms in blood
cultures clearly depends on the bacteria concentration [44,45]. Novel application of MALDI-TOF
MS has increased its potential in the detection of blood-borne organisms and thus may allow faster
bacterial identification than the conventional automated blood cultures systems in the near future [46].
However, the efficacy of MALDI-TOS MS technology in reducing the time for identifying positive
blood cultures, particularly for slow growing bacteria such as C. jejuni, remains to be evaluated.
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Since individuals with hematological disorders, especially lymphoid neoplasms, have a high
risk for infection, the close cooperation between the hematologist, infectious disease specialist, and
microbiologist can be of primary importance in providing a timely and effective intervention.
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